A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients

Loonen, Anton J. M.; Toll, P. J. M. M.; Nijdam, J.R.

doi:10.1007/bf01972911

Cited by 5 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Carbamazepine (CBZ), a widely used antiepileptic drug (AED), exhibits erratic absorption after oral ingestion with peak serum concentrations achieved within 2-8 h. Studies of various CBZ dosage formulations including suspensions, syrups, capsules and controlled release products have shown no difference in relative bioavailability (Larkin et al, 1989, Loonen et al, 1989Morselli et al, 1975;Pynnonen et al, 1978). However, differences in absorption rate, peak serum drug concentrations and time to reach peak concentrations have been noted.…”

Section: Introductionmentioning

confidence: 99%

A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.

Patsalos

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

Using an open substitution study design, conventional carbamazepine (Tegretol, CBZ‐C and a chewable carbamazepine formulation (Tegretol Chewtabs, CBZ‐CHEW) were compared in 12 patients with severe intractable epilepsy. During a dosing interval, no significant differences were observed with respect to trough or peak serum concentrations of CBZ and CBZ‐10,11‐epoxide (CBZ‐E), the active metabolite. The area under the serum CBZ concentration‐time curve for a dosing interval was (mean +/− s.e. mean) 146 +/− 10 mumols l‐1 h on CBZ‐ C and 143 +/− 9 mumols l‐1 h on CBZ‐CHEW. The two formulations, therefore, have a similar pharmacokinetic profile and could be used interchangeably in the management of patients with epilepsy.

show abstract

Section: Introductionmentioning

confidence: 99%

A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.

Patsalos

1990

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…Some of the pharmacokinetic results of this study have been published previously (Loonen et al, 1989).…”

Section: Introductionmentioning

confidence: 91%

A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients

et al. 1992

View full text Add to dashboard Cite

Twenty patients who had become accustomed to a stable oral carbamazepine dose participated in an open, randomized, two-centre, cross-over study, in which ordinary tablets and Divitabs (a new sustained release preparation) were compared. Pharmacokinetic parameters, seizure control, effects on the behavioral state, and tolerability were considered. A smaller Area Under the Curve (AUC) during the Divitabs period was the only pharmacokinetic parameter with a significant difference (p less than 0.05). However, all patients with peak/trough carbamazepine serum level ratios of at least 1.30 after the intake of the normal tablet-form (n = 9) showed a smaller peak/trough ratio during the Divitabs period. No remarkable differences were found between the normal carbamazepine preparation and Divitabs regarding seizure frequency and tolerability. The behavioral state improved in four patients during the Divitabs period, whereas no enhancement was noticed during the normal-tablet period in any of the subjects. Although this study produced no evidence that carbamazepine Divitabs were at all advantageous for the trial population in general, some of the pharmacokinetic results suggest that a subgroup of the patients would benefit from changing from the normal tablet-form to Divitabs. However, even in this subgroup, the usage of Divitabs was not shown to result in obvious clinical benefits.

show abstract

“…As this was the only reported study performed in healthy volunteers (in whom the t'l2 is longer than in epileptic patients), the diurnal fluctuations observed were less than those seen in other studies. 'Tegretol CR Divitabs' 200 to 600mg twice daily was also found to be advantageous in the treatment of psychiatric and oligophrenic patients (Loonen et al 1989).…”

Section: Carbamazepinementioning

confidence: 99%

Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs

Bialer

1992

Clinical Pharmacokinetics

View full text Add to dashboard Cite

Epilepsy is a chronic disease that requires long term therapy, and most of the established antiepileptic drugs (the exception is phenobarbital) must be administered several times daily. This results in compliance problems and fluctuations in plasma concentrations which may lead to subtherapeutic and potentially toxic levels. Development of sustained release formulations of the existing antiepileptic agents may improve antiepileptic therapy. At present, only the following 4 major drugs are used for the treatment of epilepsy: phenobarbital, phenytoin, carbamazepine and valproic acid. Of these, only the latter 2 are suitable candidates for sustained release formulations. This review, therefore, focuses on the evaluation and clinical implications of sustained release formulations of valproic acid and carbamazepine.

show abstract

A comparison of carbamazepine divitabs with carbamazepine normal formulation in psychiatric and oligophrenic patients

Cited by 5 publications

References 9 publications

A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.

A comparative pharmacokinetic study of conventional and chewable carbamazepine in epileptic patients.

A Comparison of Carbamazepine Divitabs and a Normal Carbamazepine Preparation in Psychiatric and Oligophrenic Patients

Pharmacokinetic Evaluation of Sustained Release Formulations of Antiepileptic Drugs

Contact Info

Product

Resources

About